Non-luminal breast cancers (NLBC), including human epidermal growth factor receptor-2 (HER2) positive and triple-negative breast cancers (TNBC), are characterized by aggressive clinical behavior and poor clinical outcomes [1, 2]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.